Q-omics provides the consensus-scored AGO4 profile across patient tissues and cancer cell-line models. AGO4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, AGO4 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, AGO4 RNA expression shows 20,901 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KICH, and UVM as cancer lineages where AGO4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AGO4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AGO4 survival associations across molecular data types. AGO4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AGO4 RNA expression–survival associations across cancer types. High AGO4 expression shows unfavorable associations in ACC and CESC, but favorable associations in HNSC, UCS, READ and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for AGO4 RNA expression.
This table summarizes AGO4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for AGO4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AGO4 shows lower tumor expression in KICH, BRCA, LUAD and LUSC and higher tumor expression in KIRC and CHOL. The KICH box plot shows higher AGO4 RNA expression in normal versus tumor tissue (log2 FC = −0.751, t-test p < 0.001).
This table shows molecular features associated with AGO4 in patient tissues and cancer cell lines. In patient samples, AGO4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, AGO4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
